| Issuer | % of Class | Filed |
|---|---|---|
|
Lite Strategy, Inc.
13G/A
Amendment 3
LITS · 55279B301
|
0% |
8/3/2026
Event 6/30/2026
|
|
Lite Strategy, Inc.
13G/A
Amendment 2
LITS · 55279B301
|
10.0% |
12/22/2025
Event 12/18/2025
|
|
MEI Pharma, Inc.
13G/A
Amendment 1
LITS · 55279B301
|
13.3% |
9/10/2025
Event 9/9/2025
|
|
Assembly Biosciences, Inc.
13G/A
Amendment 3
ASMB · 045396207
|
3.5% |
8/18/2025
Event 8/11/2025
|
|
MEI Pharma, Inc.
13G
LITS · 55279B301
|
6.5% |
8/12/2025
Event 8/11/2025
|
|
Assembly Biosciences, Inc.
13G
ASMB · 045396207
|
4.7% |
8/12/2025
Event 8/11/2025
|
|
Assembly Biosciences, Inc.
13G/A
Amendment 1
ASMB · 045396207
|
10.0% |
12/23/2024
Event 12/19/2024
|
|
Assembly Biosciences, Inc.
13G
ASMB · 045396207
|
10.0% |
12/23/2024
Event 6/24/2024
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.